Background. The prevalence of adrenal insufficiency (AI) in cystic fibrosis (CF) is unknown. The frequent use of glucocorticoids (inhaled or systemic) may induce the long-term suppression of the hypothalamic-pituitary-adrenal axis. Methods. We reviewed the results of adrenocorticotropic hormone (ACTH) stimulation tests done over a 10-year period to evaluate adrenal function in 69 CF patients of the CHUM CF clinic. Clinical characteristics of AI patients were compared to adrenal-sufficient (AS) patients. Results. AI was confirmed in 33 of the 69 CF patients. A higher rate of dysglycemia ($P = 0.022$) and of Aspergillus positive culture ($P = 0.006$) was observed in AI patients compared to AS patients. Weight, CFTR genotype, and pulmonary function were comparable between AI and AS patients. The use of systemic corticosteroids (SC) prior to the diagnosis of AI was observed in 42.4% of patients. Compared to AI patients without SC, SC-treated AI patients were older and had a higher rate of allergic bronchopulmonary aspergillosis. Conclusion. This study is the first to systematically examine the presence of AI in the largest cohort of CF patients studied to date with a prevalence of 8%. Patients treated with corticosteroids and those colonized with Aspergillus have a greater risk of AI.

1. Introduction

Adrenal insufficiency (AI) is the result of decreased hormonal production from the cortex of the adrenal gland. AI may be caused by adrenal failure itself (primary AI) or by disease of the pituitary or hypothalamus (secondary or tertiary AI, resp.). The most common cause of secondary AI, however, results from the chronic therapeutic use of glucocorticoids which can suppress the hypothalamic-pituitary-adrenal axis (HPA) and lead to insufficient cortisol production in response to stress [1]. AI is associated with a potential risk of adrenal crisis and severe complications if the diagnosis is delayed. The short adrenocorticotropic hormone (ACTH) stimulation test (Cortrosyn 250 μg) is the most commonly used dynamic evaluation to confirm the diagnosis of AI [2].

Although AI induced by inhaled corticosteroids (ICSs) has been documented in asthmatic adult populations [3], no studies have evaluated the prevalence of AI in the adult cystic fibrosis (CF) population. Trials on the use of ICSs in CF for the treatment of allergic bronchopulmonary aspergillosis did not systematically evaluate adverse events, although the total daily dose of ICSs was at the threshold of adrenal suppression in most studies [4]. To date, there have been only a few case reports of HPA axis suppression in patients with CF caused by the combination of ICSs (mainly fluticasone) and itraconazole, which inhibits cytochrome P450 consequently decreasing the metabolic clearance of ICSs [5–7].

Our clinical experience at the Centre hospitalier de l’Université de Montréal (CHUM) CF clinic suggests a nonnegligible prevalence of AI among our patients. Therefore, we reviewed the results of the ACTH stimulation test.
test performed over a 10-year period to evaluate adrenal function in 69 CF patients and compared the clinical characteristics of CF patients with AI to those of adrenal-sufficient (AS) patients.

2. Methods

This is a cross-sectional retrospective study approved by the Research Ethics Committee and CHUM Institutional Review Committee. This work was carried out in accordance with the Declaration of Helsinki (1964). The records of 385 patients attending the CF clinic between January 1, 2007, and December 31, 2016, were reviewed. Cases were selected from the CF clinic database and from the computerized laboratory system at CHUM. Inclusion criteria for the study were (1) age 18 or more and (2) a documented ACTH stimulation test (Cortrosyn stimulation test).

Two different ACTH stimulation tests have been performed: the low dose (LDCT, Cortrosyn 1 μg) and the high dose (HDST, Cortrosyn 250 μg). The HDST and the LDCT are the alternative less-invasive methods used in hospitals and clinics to assess adrenal function in patients with suspected chronic AI. However, several meta-analysis studies have demonstrated that the LDCT is more sensitive than the HDST to diagnose secondary AI, such as in patients taking corticosteroids, since the HDST uses supraphysiologic doses of ACTH [8, 9]. For these reasons, the LDCT is now preferred. The LDCT must be done by people well-informed in the preparation and the administration of the 1 μg Cortrosyn [10]. To ensure appropriate testing at our CHUM clinic, the hospital pharmacist is responsible for preparing the Cortrosyn syringe and the nurse uses this preparation to perform the test. In both tests, plasma cortisol levels were measured at baseline as well as 30 and 60 minutes after intravenous injection. Normal adrenal function was defined as a minimum plasma cortisol concentration of 500–550 nmol/L before or after ACTH injection in both low-dose and high-dose tests. When peak cortisol was below this threshold, the diagnosis of AI was confirmed and treatment with hydrocortisone (Cortef) was started. Patients with CF who underwent an organ transplantation were excluded from the study. Of the 69 CF patients that underwent an ACTH functional test, 36 were categorized as AS, whereas 33 were diagnosed with AI. Amongst the 36 patients with AS, 33 underwent the LDCT, 2 did the HDST, and 1 patient did an insulin tolerance test [11]. Between the 33 patients with AI, 28 did the LDCT, 2 underwent the HDST, and 3 were diagnosed with AI because they had undetectable (significantly low concentrations in the laboratory results) plasma cortisol levels. Physicians of the CF clinics will prescribe the ACTH test if the patient has a low blood cortisol concentration in the morning. This screening is done once a year with the routine biochemistry monitoring of the patient’s condition. An ACTH test is also prescribed if the patient is experiencing significant fatigue that is unrelated to his clinical status. In other words, the patient feels always tired and does not have a lot of energy, in presence of stable lung function and weight and in absence of significant systemic inflammation.

Demographics (age, sex, weight, and body mass index (BMI)), pulmonary disease characteristics (forced expiratory volume in 1 sec (FEV1), forced vital capacity (FVC), residual volume (RV), oxygen dependence, CFTR genotype, and noninvasive ventilation support), comorbidities (pancreatic and hepatic dysfunction as evidenced by abnormal level of hepatic enzymes or presence of cirrhosis), dysglycemia (diabetes or impaired glucose tolerance), allergic broncho-pulmonary aspergillosis (ABPA), microbiological data (bacteria, fungi, and non-TB mycobacteria), biochemical and hematological data (median value over the past year of hemoglobin and white blood cells, and fasting serum cortisol), and results of the functional ACTH test were collected from all of the patients. The total number of intravenous antibiotic treatments and hospitalizations during the two years preceding the diagnosis of AI as well as the use of ICSs, systemic corticosteroids, and chronic antibiotic therapy (inhaled) were also documented.

Values are expressed as median and interval range for each study group (AS versus AI, and AI with or without systemic corticosteroid). Statistical significance of the differences between study groups was determined by Mann-Whitney Student’s t-test, as well as by chi-square (chi²) regression analysis for genotype and hepatic function. All statistical analyses were done with SPSS for Windows software (version 17.0, SPSS Inc., Chicago, IL, USA). A probability value of $P \leq 0.05$ was considered statistically significant.

3. Results

Over the 10-year period, 385 patients diagnosed with CF were seen at the CHUM CF clinic. In this group of CF patients, 69 patients underwent functional tests, of which 36 patients (41.7% men) had normal responses (AS) and 33 patients (48.5% men) had a confirmed diagnosis of AI. From these data, the prevalence of AI in this cohort was calculated to be 8.6%. Their clinical characteristics are detailed in Tables 1 and 2. The median age and BMI of CF patients with AI were comparable to those that had AS (28.0 years and 21.6 kg/m² versus 30 years and 20.9 kg/m², resp.) (Table 1). The most frequent genotype was the homozygous delta F508 mutation in both AS and AI (58.3% and 60.6%, resp.). Interestingly, the proportion of patients with dysglycemia was statistically higher in AI patients compared to AS patients (87.9% versus 63.9%, $P = 0.022$). Pancreatic insufficiency, hepatic dysfunction, and presence of ABPA were not increased in AI patients. No difference was observed when comparing parameters of the pulmonary function test (FEV1, FVC, and RV) as well as WBC values between both adrenal function groups (Table 2). Patients with AI were more likely to take ICSs and less prone to use chronic inhaled antibiotics ($P = 0.005$, Table 2). However, the number of hospitalization and the number of IV antibiotic treatments 2 years prior to diagnosis were comparable between AS and AI patients. Finally, the sole microorganisms that had a significant difference of proportionality between AS (17.1%) and AI (48.5%) patients were Aspergillus and fungi ($P = 0.006$, Table 2).
now, only individual case reports relating CF and AI have appeared in the literature. This is the first study that characterizes a large group of adult patients with CF that had developed AI. Our observations show that, compared to the AS subgroup, the AI subgroup of CF patients exhibited a higher frequency of dysglycemia and had a higher percentage of patients colonized with Aspergillus/fungi. AI patients on systemic corticosteroids were also older. Finally, the utilization of ICSs or systemic corticosteroids was more frequent in patients with AI. More interestingly, more than half the AI patients on systemic corticosteroids had ABPA compared to none in the subgroup of patients not taking systemic corticosteroids.

We are the first to estimate the prevalence of AI in an adult CF population. Our data, obtained following review of the clinical records of over 385 CF patients, suggest that the prevalence of AI in our CF population is between 8% and 9%. This value may be underestimated due to the difficulty of recognizing AI and the lack of systematic screening. Although significant, this prevalence is much lower than the one that has been observed in non-CF bronchiectasis. Indeed, in a study of 40 consecutive patients with non-CF bronchiectasis, Rajagopala et al. [12] reported that 40% of patients had a reduced response to functional testing. No association with inhaled or oral corticosteroids therapy, or severity of impairment was identified in this study. In a British study of non-CF bronchiectasis, adrenal suppression was found in 23.5% of subjects not receiving ICSs and in 48.5% of patients receiving it [13]. Skov et al. observed AI in 11 out of 25 patients with CF treated both with itraconazole for ABPA and budesonide [14], while one of the 11 patients treated with itraconazole alone (without budesonide) had AI. More recently, Gilchrist et al. found a higher prevalence of HPA axis suppression in 10 out of 12 patients with CF receiving both itraconazole and inhaled fluticasone compared

### Table 1: Clinical characteristics of patients with CF according to their adrenal function (N = 69).

|                      | Sufficient | Insufficient | P value |
|----------------------|------------|--------------|---------|
| **Demographic**      |            |              |         |
| Number of patients   | 36         | 33           |         |
| Sex (% men)          | 41.7       | 48.5         | 0.572   |
| Age (years)          | 30.0 (19.0–67.0) | 28.0 (19.0–55.0) | 0.648   |
| Weight (kg)          | 54.1 (42.3–83.9) | 61.0 (41.1–79.1) | 0.084   |
| BMI (kg/m²)          | 20.9 (17.5–28.6) | 21.6 (17.1–27.5) | 0.079   |
| Genotype (% yes)     |            |              |         |
| Homozygote delF508   | 58.3       | 60.6         |         |
| Heterozygote delF508 | 38.9       | 30.3         | 0.458*  |
| Others               | 2.8        | 9.1          |         |
| **Comorbidities**    |            |              |         |
| Glucose tolerance (% yes) |     |              |         |
| Normal               | 36.1       | 12.1         | 0.022   |
| Dysglycemic          | 63.9       | 87.9         | 0.022   |
| Pancreatic insufficiency (% yes) | |              |         |
| 91.7                 | 87.9       | 0.605        |
| Hepatic dysfunction (% yes) | |              |         |
| 30.3                 | 11.1       | 0.041        |
| Home oxygen therapy (% yes) | |              |         |
| 5.6                  | 15.2       | 0.190        |
| Noninvasive ventilation (% yes) | |              |         |
| 2.8                  | 6.1        | 0.507        |
| ABPA (% yes)         | 16.7       | 27.3         | 0.290   |

BMI, body mass index; dysglycemic is presence of either glucose intolerance or diabetes; hepatic dysfunction is either abnormal level of hepatic enzymes or presence of cirrhosis; ABPA, allergic bronchopulmonary aspergillosis. Median and interval range are shown. P value ≤ 0.05 represents Mann-Whitney Student’s t-test. *Chi² regression analysis.

Systemic corticosteroid therapy prior to the diagnosis of AI was observed in 14 patients with a median duration of administration of 18 months (varying between 1 week and 74 months) (Table 2). Of these 14 patients, all but one received corticosteroids for more than a month in the year prior to the diagnosis. When comparing with AI patients who did not receive systemic corticosteroids, AI patients taking systemic corticosteroids were older (36.0 years versus 26.0 years, P = 0.019) (Table 3). Interestingly, the use of systemic corticosteroids was justified by the diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in 9 cases (64.3%). In addition, AI patients with systemic corticosteroid had significantly lower levels of cortisol at 30 minutes during the ACTH stimulation test (P = 0.047). Treatment with systemic corticosteroids was not associated with antifungal treatment. The median number of hospitalizations and of intravenous antibiotic treatments in the two years preceding the diagnosis and the profile of bacterial and fungal infection and medication are detailed in Table 4. ICSs were used in 92.9% of AI patients with systemic corticosteroids. In the 19 patients who had no recent exposure (<2 years) to systemic corticosteroids, all but one were using ICSs. The ICSs used were fluticasone or budesonide mainly at high dosage and sometimes in combination with ciclesonide. The detailed clinical findings of these patients are reported in Tables 3 and 4.

The chronic use of opiates was the suspected etiology of AI in 2 cases. The prolonged intake of voriconazole for the treatment of Scedosporium apiospermum was observed in 2 patients. Use of other antifungal agents in the Montreal CF cohort has not been identified (data not shown).

### 4. Discussion

AI is the inability to produce sufficient amount of steroid hormones (primarily cortisol) from the adrenal glands. Until
to patients with CF receiving inhaled fluticasone alone [15]. In all these studies, there was a selection of patients based on either the therapy administered or their clinical status. This might explain the difference in the prevalence observed. A prospective study will be necessary to determine more precisely the prevalence of this condition in CF.

Dysglycemia and Aspergillus/fungi colonization also appear as potential risk factors for AI. Our study showed an increased prevalence of dysglycemia (87.9%) in AI compared to AS patients (63.9%). Although this association could be secondary to the chronic inflammatory response associated with diabetes, it could also be a confounding factor since it is well known that chronic use of corticosteroids can lead to heightened blood glucose levels and diabetes [16]. Chronic inflammatory response associated with CF could also explain the presence of AI in patients who did not take corticosteroids. Indeed, Mastorakos et al. have demonstrated that prolonged inflammatory stress induced by a sustained high level of interleukin-6 (IL-6) decreases the reactivity of the HPA axis over time [17]. Inadequate cortisol production has also been demonstrated in rheumatologic patients. The study by Straub et al. showed that levels of ACTH and cortisol, when related to IL-6 and TNF, were relatively lower in untreated patients with early rheumatoid arthritis and reactive arthritis as compared to healthy subjects [18]. Noni et al. reported an association between Aspergillus colonization and duration of ICS treatment [19]. A future case-control study is needed to validate these findings, to more precisely determine the real prevalence of AI and its risk factors, and to evaluate the clinical course and repercussions of AI on the quality of life of CF patients. Our observations suggest that CF patients who have an abnormal glucose status (glucose intolerant or CF-related diabetes) or are colonized with Aspergillus/fungi or have received systemic corticosteroids as well as have ABPA might benefit from a systematic screening of adrenal function.

Clearly, the utilization of corticosteroids plays a major role in the suppression of the HPA axis in CF patients. In our study, the majority of patients with AI were treated with ICSs for several years. Although the therapeutic use of ICSs remains controversial in the management of CF [4, 20], it remains widespread. There are multiple factors that might explain the association between ICS use and AI in CF. First, chronic airway inflammation is associated with pathological

| Table 2: Paraclinical characteristics of patients with CF according to their adrenal function (N = 69). |
|---------------------------------------------------------------|
| **Pulmonary function test**                                  | Sufficient | Insufficient | P value |
| FEV1 (% pred)                                                | 44.6 (22.0–120.0) | 52.9 (27.5–82.6) | 0.509 |
| FVC (% pred)                                                 | 69.9 (32.8–113.8) | 72.6 (51.0–97.8) | 0.885 |
| RV (% pred)                                                  | 177.0 (80.0–414.0) | 197.5 (126.0–406.0) | 0.271 |
| **Biochemistry**                                             |             |             |         |
| Fasting cortisol (nmol/L)                                    | 421.0 (191.0–954.0) | 146.0 (12.0–335.0) | ≤0.001 |
| Cortisol (nmol/L)                                            |             |             |         |
| 1 μg functional cortrosyn test (n)                           | 33          | 28          |         |
| 0 minutes                                                    | 388.0 (113.0–852.0) | 139.5 (10.0–382.0) | ≤0.001 |
| 30 minutes                                                   | 628.0 (502.0–1079.0) | 354.0 (25.0–491.0) | ≤0.001 |
| 60 minutes                                                   | 510.0 (210.0–902.0) | 305.0 (23.0–457.0) | ≤0.001 |
| 250 μg functional cortrosyn test (n)                         | 2           | 2           |         |
| 0 minutes                                                    | 426.5 (407.0–446.0) | 158.5 (26.0–291.0) | NA |
| 30 minutes                                                   | 637.5 (606.0–669.0) | 325.5 (179.0–472.0) | NA |
| 60 minutes                                                   | 678.0 (664.0–692.0) | 309.5 (238.0–381.0) | NA |
| **Hematology**                                               |             |             |         |
| WBC (10^9/L)                                                 | 7.6 (4.1–10.8) | 8.0 (2.55–17.5) | 0.294 |
| **Medication**                                               |             |             |         |
| Systemic corticosteroids (% yes)                             | 0           | 42.4        | ≤0.001 |
| Duration (months)                                            | —           | 18.0 (0.25–74.0) | — |
| Inhaled corticosteroids (% yes)                              | 66.7        | 93.9        | 0.005 |
| Chronic inhaled antibiotic (% yes)                           | 100.0       | 78.8        | 0.005 |
| **Medical history**                                          |             |             |         |
| Number of hospitalizations (2 years prior to diagnosis)      | 2.0 (0–8.0) | 2.0 (0–11.0) | 0.593 |
| Number of intravenous antibiotic treatments (2 years prior to diagnosis) | 3.0 (0–8.0) | 3.0 (0–11.0) | 0.565 |
| **Colonization/microbiology**                                |             |             |         |
| Non-TB mycobacteria (% yes)                                  | 8.6         | 3.0         | 0.353 |
| Staphylococcus aureus (% yes)                                | 31.4        | 39.4        | 0.495 |
| Pseudomonas aeruginosa (% yes)                               | 77.1        | 81.8        | 0.636 |
| Aspergillus and fungi (% yes)                                | 17.1        | 48.5        | 0.006 |
| Stenotrophomonas maltophilia (% yes)                         | 25.0        | 30.3        | 0.625 |
| Others (% yes)                                               | 19.4        | 12.1        | 0.410 |

FEV1, forced expiratory volume-one second; FVC, forced vital capacity; RV, residual volume; WBC, white blood cell count; TB, tuberculous; NA, not applicable. Median and interval range are shown. P value < 0.05 represents Mann-Whitney Student’s t-test.
### Table 3: Clinical characteristics of adrenal insufficient patients with CF with and without systemic corticosteroids (N = 33).

| Systemic corticosteroids | Yes | No | P value |
|--------------------------|-----|----|---------|
| **Demographic**          |     |    |         |
| Number of patients       | 14  | 19 |         |
| Sex (% men)              | 35.7| 57.9| 0.215   |
| Age (years)              | 36.0 (21.0–55.0) | 26.0 (19.0–39.0) | 0.019 |
| Weight (kg)              | 58.8 (50.0–79.1) | 61.2 (41.1–72.8) | 0.913 |
| BMI (kg/m²)              | 21.3 (19.1–27.4) | 21.7 (17.1–27.5) | 0.971 |
| **Genotype (% yes)**     |     |    |         |
| Homozygote delF508       | 57.1| 63.2|         |
| Heterozygote delF508     | 35.7| 26.3| 0.825*  |
| Others                   | 7.1 | 10.5|         |
| **Comorbidities**        |     |    |         |
| Glucose tolerance (% yes)|     |    |         |
| Normal                   | 7.1 | 15.8| 0.459   |
| Dysglycemic              | 92.9| 84.2| 0.459   |
| Pancreatic insufficiency (% yes) | 71.4 | 100.0 | 0.014 |
| Hepatic dysfunction (% yes) | 21.4 | 36.8 | 0.208 |
| Home oxygen therapy (% yes) | 7.1 | 21.1 | 0.278 |
| Noninvasive ventilation (% yes) | 0  | 10.5 | 0.217 |
| ABPA (% yes)             | 64.3| 0   | ≤0.001  |

BMI, body mass index; dysglycemic is presence of either glucose intolerance or diabetes; hepatic dysfunction is either abnormal level of hepatic enzymes or presence of cirrhosis; ABPA, allergic bronchopulmonary aspergillosis. Median and interval range are shown. P value < 0.05 represents Mann-Whitney Student’s t-test. *Chi² regression analysis.

### Table 4: Paraclinical characteristics of adrenal insufficient patients with CF with and without systemic corticosteroids (N = 33).

| Systemic corticosteroids | Yes | No | P value |
|--------------------------|-----|----|---------|
| **Pulmonary function test**|     |    |         |
| FEV1 (% pred)            | 56.9 (28.6–73.7) | 44.1 (27.5–82.6) | 0.536 |
| FVC (% pred)             | 75.3 (51.0–96.4) | 68.6 (56.4–97.8) | 0.466 |
| RV (% pred)              | 188.5 (128.0–221.0) | 238.0 (126.0–406.0) | 0.051 |
| **Biochemistry**         |     |    |         |
| Fasting cortisol (nmol/L)| 134.0 (25.0–254.0) | 169.5 (12.0–335.0) | 0.323 |
| Cortisol (nmol/L)        |     |    |         |
| 1 µg functional cortrosyn test (n) | 10  | 18 |         |
| 0 minutes                | 124.5 (25.0–219.0) | 167.0 (10.0–382.0) | 0.415 |
| 30 minutes               | 314.0 (86.0–425.0) | 398.5 (25.0–491.0) | 0.179 |
| 60 minutes               | 279.0 (64.0–457.0) | 315.5.0 (23.0–425.0) | 0.388 |
| 250 µg functional cortrosyn test (n) | 1  | 1 |         |
| 0 minutes                | 26.0 | 291.0 | NA    |
| 30 minutes               | 179.0 | 472.0 | NA    |
| 60 minutes               | 238.0 | 381.0 | NA    |
| **Hematology**           |     |    |         |
| WBC (10⁹/9/L)            | 9.4 (4.9–17.5) | 7.6 (2.6–15.0) | 0.074 |
| **Medication**           |     |    |         |
| Inhaled corticosteroids (% yes) | 92.9 | 94.7 | 0.823 |
| Inhaled chronic antibiotic therapy (% yes) | 78.6 | 78.9 | 0.979 |
| **Medical history**      |     |    |         |
| Number of hospitalizations (2 years prior to diagnosis) | 2.0 (0–6.0) | 4.0 (0–11) | 0.151 |
| Number of intravenous antibiotic treatments (2 years prior to diagnosis) | 2.5 (0–7.0) | 4.0 (0–11) | 0.212 |
| **Colonization/microbiology** |     |    |         |
| Non-TB mycobacteria (% yes) | 7.1 | 0  | 0.244 |
| Staphylococcus aureus (% yes) | 42.9 | 36.8 | 0.731 |
| Pseudomonas aeruginosa (% yes) | 71.4 | 89.5 | 0.191 |
| Aspergillus and fungi (% yes) | 50.0 | 47.4 | 0.883 |
| Stenotrophomonas maltophilia (% yes) | 28.6 | 31.6 | 0.826 |
| Others (% yes)           | 14.3 | 10.5 | 0.747 |

FEV1, forced expiratory volume-one second; FVC, forced vital capacity; RV, residual volume; WBC, white blood cell count; TB, tuberculous; NA, not applicable. Median and interval range are shown. P value < 0.05 represents Mann-Whitney Student’s t-test.
angiogenesis in the airway [21, 22]. It is suggested that this increase in vascularization in the airway and lungs might lead to increased absorption of corticosteroids into the systemic circulation. Second, since a significant quantity of inhaled corticosteroid is swallowed into the digestive tract, the use of high doses will lead to increased levels in the systemic circulation [23]. Besides absorption, other factors play an important role in the suppression of the HPA axis by ICSs. Indeed, the bioavailability of inhaled compounds is not uniform [24]. Therefore, the ICS compound that has the lowest oral bioavailability would be the best option to decrease undesired corticosteroid effects [24, 25]. Other factors that can affect corticosteroid availability include systemic clearance, receptor affinity, and protein binding capacity [24]. Finally, plasma cortisol concentration varies significantly during the day, with the highest levels measured early in the morning at around 8 AM and the lowest at midnight [24]. Thus, to minimize the secondary effects of corticosteroids on cortisol suppression, it becomes important to consider the elimination half-life of the inhaled compound as well as the drug administration time so that the peak drug level is in phase with the natural cycle of endogenous cortisol. Additional studies are essential to study the pharmacodynamics of ICSs specifically in CF.

The ACTH stimulation test requires multiple steps for its preparation, and it has to be done by experienced personnel and is time consuming. Identifying and proposing a management plan where ACTH stimulation is not the primary test that is done but it should be used only to confirm the diagnosis before beginning therapy would be important [26]. A potential management plan including an easy screening tool that can be done during a routine clinical visit will need to be evaluated in future studies.

5. Conclusion

This study is the first to systematically examine adrenal function in a cohort of CF patients. Our analysis would suggest that the prevalence of AI is at least 8% in our adult CF clinic. Therapeutic use of inhaled and systemic corticosteroids was often identified in patients with adrenal suppression. Considering the lack of clear clinical benefit of ICS therapy in CF, our results show the need for additional studies to reduce both the burden of medication and the potential adverse effects of corticosteroid therapy in CF patients.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors thank all CF patients who participated in this study. Funding from the Lamarre-Gosselin Chair supported Yves Berthiaume, and a Cystic Fibrosis Canada Postdoctoral Fellowship supported Adèle Coriati.

References

[1] F. Guerrero Perez, A. P. Marengo, and C. Villabona Artero, “The unresolved riddle of glucocorticoid withdrawal,” Journal of Endocrinological Investigation, vol. 40, no. 11, pp. 1175–1181, 2017.
[2] A. Agha, J. W. Tomlinson, P. M. Clark, G. Holder, and P. M. Stewart, “The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic-pituitary-adrenal axis,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 43–47, 2006.
[3] J. H. Wlodarczyk, P. G. Gibson, and M. Caeser, “Impact of inhaled corticosteroids on cortisol suppression in adults with asthma: a quantitative review,” Annals of Allergy, Asthma & Immunology, vol. 100, no. 1, pp. 23–30, 2008.
[4] I. M. Balfour-Lynn and K. Welch, “Inhaled corticosteroids for cystic fibrosis,” Cochrane Database of Systematic Reviews, no. 10, p. CD001915, 2014.
[5] J. S. Parmar, T. Howell, J. Kelly, and D. Bilton, “Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis,” Thorax, vol. 57, no. 8, pp. 749-750, 2002.
[6] K. M. Main, M. Skov, I. B. Silleisen et al., “Cushing’s syndrome due to pharmacological interaction in a cystic fibrosis patient,” Acta Paediatrica, vol. 91, no. 9, pp. 1008–1011, 2002.
[7] B. B. Albert, M. Jaksic, J. Ramirez et al., “An unusual cause of growth failure in cystic fibrosis: a salutary reminder of the interaction between glucocorticoids and cytochrome P450 inhibiting medication,” Journal of Cystic Fibrosis, vol. 14, no. 4, pp. e9–e11, 2015.
[8] M. Magnotti and M. Shimshi, “Diagnosing adrenal insufficiency: which test is best—the 1-microg or the 250-microg cosyntropin stimulation test?,” Endocrine Practice, vol. 14, no. 2, pp. 233–238, 2008.
[9] S. M. Ng, J. C. Agwu, and K. Dwan, “A systematic review and meta-analysis of Synacthen tests for assessing hypothalamic-pituitary-adrenal insufficiency in children,” Archives of Disease in Childhood, vol. 101, no. 9, pp. 847–853, 2016.
[10] A. K. Younes and N. K. Younes, “Recovery of steroid induced adrenal insufficiency,” Translational Pediatrics, vol. 6, no. 4, pp. 269–273, 2017.
[11] V. De Sanctis, A. Soliman, M. Yassin, and P. Garofalo, “Cortisol levels in central adrenal insufficiency: light and shade,” Pediatric Endocrinology Reviews, vol. 12, no. 3, pp. 283–289, 2015.
[12] S. Rajagopala, A. Ramakrishnan, G. Bantwal et al., “Adrenal insufficiency in patients with stable non-cystic fibrosis bronchiectasis,” Indian Journal of Medical Research, vol. 139, no. 3, pp. 393–401, 2014.
[13] J. Holme, J. W. Tomlinson, R. A. Stockley, P. M. Stewart, N. Barlow, and A. L. Sullivan, “Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids,” European Respiratory Journal, vol. 32, no. 4, pp. 1047–1052, 2008.
[14] M. Skov, K. M. Main, I. B. Sillelesen, J. Muller, C. Koch, and S. Lang, “Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide,” European Respiratory Journal, vol. 20, no. 1, pp. 127–133, 2002.
[15] F. J. Gilchrist, K. J. Cox, R. Rowe et al., “Itraconazole and inhaled fluticasone causing hypothalamic-pituitary-adrenal axis suppression in adults with cystic fibrosis,” Journal of Cystic Fibrosis, vol. 12, no. 4, pp. 399–402, 2013.
[16] G. Di Dalmazi, U. Pagotto, R. Pasquali, and V. Vicennati, “Glucocorticoids and type 2 diabetes: from physiology to
pathology,” *Journal of Nutrition and Metabolism*, vol. 2012, Article ID 525093, 9 pages, 2012.

[17] G. Mastorakos, G. P. Chrousos, and J. S. Weber, “Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans,” *Journal of Clinical Endocrinology and Metabolism*, vol. 77, no. 6, pp. 1690–1694, 1993.

[18] R. H. Straub, L. Paimela, R. Peltonmaa, J. Scholmerich, and M. Leirisalo-Repo, “Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis,” *Arthritis & Rheumatism*, vol. 46, no. 3, pp. 654–662, 2002.

[19] M. Noni, A. Katelari, G. Dimopoulos et al., “Inhaled corticosteroids and *Aspergillus fumigatus* isolation in cystic fibrosis,” *Medical Mycology*, vol. 52, no. 7, pp. 715–722, 2014.

[20] K. Cheng, D. Ashby, and R. L. Smyth, “Oral steroids for long-term use in cystic fibrosis,” *Cochrane Database of Systematic Reviews*, no. 12, p. CD000407, 2015.

[21] E. M. Wagner, J. Jenkins, M. G. Perino, A. Sukkar, and W. Mitzner, “Lung and vascular function during chronic severe pulmonary ischemia,” *Journal of Applied Physiology*, vol. 110, no. 2, pp. 538–544, 2011.

[22] S. A. McColley, V. Stellmach, S. R. Boas, M. Jain, and S. E. Crawford, “Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation,” *American Journal of Respiratory and Critical Care Medicine*, vol. 161, no. 6, pp. 1877–1880, 2000.

[23] E. H. Bel, S. E. Wenzel, P. J. Thompson et al., “Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma,” *New England Journal of Medicine*, vol. 371, no. 13, pp. 1189–1197, 2014.

[24] H. Derendorf, G. Hochhaus, B. Meibohm, H. Mollmann, and J. Barth, “Pharmacokinetics and pharmacodynamics of inhaled corticosteroids,” *Journal of Allergy and Clinical Immunology*, vol. 101, no. 4, pp. S440–S446, 1998.

[25] D. B. Allen, “Effects of inhaled steroids on growth, bone metabolism and adrenal function,” *Expert Review of Respiratory Medicine*, vol. 1, no. 1, pp. 65–74, 2007.

[26] C. P. Woods, N. Argese, M. Chapman et al., “Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol,” *European Journal of Endocrinology*, vol. 173, no. 5, pp. 633–642, 2015.